Pennsylvania Injury Lawyer Blog

Actos is an equal opportunity Type 2 diabetes drug that causes bladder cancer in men and women. While both sexes are at risk, men are more at risk.

However, women who take Actos for type 2 diabetes not only are at risk for bladder cancer but are also at risk for fractures known as secondary osteoporosis.

What is worse? Women, what’s worse diabetes or the cure? Type 2 diabetes is manageable with a complementary prescription drug and nutrition. But bladder cancer and bone fractures?

At the School of Medicine, Health Policy and Practice, University of East Anglia in Norwich, UK, their study aimed to determine the risk of fractures associated with thiazolidinedione therapy and to evaluate the effect on bone density. Pioglitazone (Actos) and Rosiglitazone (Avandia) are in the thiazolidinedione (TZD) class of drugs.

For the purpose of the blog post, let’s focus on Actos.

Continue reading "Bone fractures, Actos and bladder cancer in women" »

This past June, government officials in France and Germany removed the diabetes medication Actos (pioglitazone) from their markets after a study by French researchers discovered a correlation between the drug and an elevated risk of bladder cancer. However, even though the U.S. Food and Drug Administration (FDA) issued a public cautionary statement about the risk and updated the warning information on the product’s label and patient information, Actos and other drugs containing pioglitazone are still available on the U.S. market.

Actos is a leading medicine in a small class of drugs to treat blood sugar levels in Type II diabetes. The FDA said that from January 2010 to October 2010, approximately 2.3 million people received prescriptions for Actos or another drug with pioglitazone. In 2009, Actos sales in the U.S. were around $3.4 billion, as reported by The New York Times. Other drugs it is used in tandem with are Actoplus Met, Actoplus Met XR, and Duetact. The FDA’s warning claims that the Actos bladder cancer risk is highest for individuals using the drug on a long term basis, over a year, and in larger increasing dosages.

An increasing amount of individuals in the U.S. have started a class action lawsuit against the company that makes Actos. Users affected or injured by drug claim that the company did not adequately investigate the drug prior to releasing it on the market and also failed to inform the public of its serious dangers. If you’ve used Actos, or have been harmed by the drug (or any drug containing pioglitazone), contact the Pennsylvania dangerous drug attorneys with Anapol Schwartz at (866) 735-2792 for a free case review with an attorney.

After the U.S. Food and Drug Administration (FDA) cautioned in June that the diabetes drug pioglitazone (known as brand name “Actos”) presents an increased risk of bladder cancer for ongoing users, the start of a class action lawsuit involving dozens of affected individuals quickly followed in September.

Specifically, the drug is prescribed to adults with type 2 diabetes mellitus to assist with the regulation of blood sugar. From January 2010 to October 2010, the FDA reported about 2.3 million individuals with prescriptions that contained the substance. In addition to Actos, pioglitazone is also found in Actoplus Met, Actoplus Met XR, and Duetact.

The FDA issued the following guidelines regarding Actos, and any other medical products containing the drug:

• Do not prescribe it to patients with bladder cancer.
• Use the drug with discretion with an individual with a medical history of bladder cancer.

Other than the stated primary risk, the agency also gave consumers and patients the following instructions:

• Do not use the drug if you are receiving treatment for bladder cancer.
• Immediately notify your health care professional if you experience any of these symptoms: red appearance of the presence of blood in your urine, an urgency to urinate or pain while doing so, or pain in your back or lower abdomen.

Those using any products with pioglitazone, or the primary drug Actos, are instructed by the FDA to speak with their health care provider at once. If you believe you’ve been injured by exposure to pioglitazone, contact the Pennsylvania Actos attorneys with Anapol Schwartz at 1(866)735-2792 for a free consultation.